Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Aurora Cannabis Inc.NASDAQ: ACB

Selling, General & Admin · Q4 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q4 FY2026 selling, general & admin of CA$41.51M fell 14.4% year over year, behind the +0.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.

Context

  • Selling, general & admin amounted to 54.1% of revenue in FY2026, up 5.6 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of CA$200.87M (+15.5%) for the fiscal year ending Mar 2027, a step up from the +4.5% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$41.51M+3.6% QoQ
Last fiscal yearMar 2026
CA$173.95M+4.5% YoY
LTMMar 2026
CA$166.84M+0.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.4%+13.0%+27.4 pp
1 year+4.5%+15.5%+11.0 pp
3-year CAGR+0.7%+12.2%+11.5 pp
5-year CAGR+11.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

CAD · from the income statement

Latest · FY2026
173.95M CAD
Year-over-year change
+4.5%
4-year CAGR
-2.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.2% is the 5th highest of 10, against a peer median of -1.6%.
  • Selling, general & admin amounts to 53.7% of revenue for ACB, versus a peer median of 53.9%.
ACB Competitors
Selling, General & Admin for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LFMDLifeMD, Inc.LTM Mar 2026$172.43M USD-5.1%+4.7%78.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$166.84M CAD+0.2%+0.7%53.7%
CGCCanopy Growth CorporationLTM Mar 2026CA$134.01M CAD+10.1%-9.2%42.9%
OGIOrganigram Global Inc.LTM Mar 2026CA$92.98M CAD+36.2%—33.9%
HITIHigh Tide Inc.LTM Apr 2026CA$90.78M CAD-15.3%+7.8%13.5%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$70.03M USD-34.3%-10.8%19.4%
EDITEditas Medicine, Inc.LTM Mar 2026$46.76M USD-29.2%-11.0%120.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$33.33M USD—+8.3%24.7%
BIOABioAge Labs, Inc.LTM Mar 2026$28.7M USD+27.8%+43.3%278.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$27.13M USD-1.6%-10.3%64.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M USD+5.5%-4.4%269.8%
Peer median (excluding ACB) —-1.6%-4.4%53.9%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M223.8M270.28M343.29M321.42M
Cost of Revenue200.11M209.02M138.82M155.69M304.67M
Gross Profit21.23M14.78M131.46M187.61M16.75M
Gross Margin9.6%6.6%48.6%54.6%5.2%
Research & Development10.39M5.77M3.57M3.68M6.01M
Selling, General & Admin188.99M170.48M156.88M166.47M173.95M
Operating Expenses252.67M221.98M177.91M182.66M179.96M
Depreciation & Amortization93.66M52.59M33.07M22.55M14.23M
EBITDA(1.55B)(135M)(12.34M)51.35M(148.99M)
EBITDA Margin-702.4%-60.3%-4.6%15.0%-46.4%
Operating Income(231.45M)(207.19M)(46.45M)4.95M(163.21M)
Operating Margin-104.6%-92.6%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.86M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(576.51M)(13.15M)15.43M106.54M
Income Before Tax(1.72B)(783.7M)(59.6M)20.38M(56.67M)
Pre-Tax Margin-777.1%-350.2%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)16.55M(554K)4.62M2.1M
Net Income(1.72B)(816.63M)(69.33M)1.59M(122.07M)
Net Margin-776.0%-364.9%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.